Results 31 to 40 of about 221,455 (333)

Ibrutinib plus Bendamustine and Rituximab in Untreated Mantle-Cell Lymphoma.

New England Journal of Medicine, 2022
BACKGROUND Ibrutinib, a Bruton's tyrosine kinase inhibitor, may have clinical benefit when administered in combination with bendamustine and rituximab and followed by rituximab maintenance therapy in older patients with untreated mantle-cell lymphoma ...
Michael L. Wang, W. Jurczak, M. Jerkeman, J. Trotman, P. Zinzani, D. Belada, C. Boccomini, I. Flinn, P. Giri, A. Goy, P. Hamlin, O. Hermine, J. Hernandez-rivas, X. Hong, S. Kim, D. Lewis, Y. Mishima, M. Özcan, G. Perini, C. Pocock, Yu-Qin Song, S. Spurgeon, J. Storring, J. Walewski, Jun Zhu, R. Qin, T. Henninger, S. Deshpande, A. Howes, S. le Gouill, M. Dreyling   +30 more
semanticscholar   +1 more source

Rituximab resistance [PDF]

Best Practice & Research Clinical Haematology, 2011
Rituximab has become a ubiquitous component of treatment regimens for follicular non-Hodgkin lymphoma. Despite widespread clinical use, the mechanisms by which tumor cells resist rituximab-mediated destruction remain unclear. Rituximab relies in part on immune effector mechanisms for its antitumor effect, and thus resistance may be mediated not only by
Andrew R, Rezvani, David G, Maloney
openaire   +2 more sources

Efficacy and Safety of Rituximab for New-Onset Generalized Myasthenia Gravis

JAMA Neurology, 2022
This randomized clinical trial investigates the efficacy and safety of rituximab compared vs placebo as an add-on with standard of care for myasthenia gravis.
F. Piehl, Ann Eriksson-Dufva, Anna Budzianowska, Amalia Feresiadou, William Hansson, M. Hietala, I. Håkansson, Rune Johansson, D. Jons, I. Kmezic, C. Lindberg, J. Lindh, F. Lundin, I. Nygren, A. Punga, R. Press, K. Samuelsson, P. Sundström, O. Wickberg, S. Brauner, T. Frisell   +20 more
semanticscholar   +1 more source

Is it the time to offer rituximab as a cost-benefit treatment for immunoglobulin A nephropathy? A short-review to current concepts [PDF]

Journal of Nephropathology, 2018
Context: IgA nephropathy (IgAN) as an autoimmune disease is the most common cause of glomerulonephritis worldwide. Rituximab effectively depletes B cells and reduces serum levels of IgA1 antibodies.
Mohammad-Reza Tamadon, Jamileh Moghimi, Hamed Rezaei   +2 more
doaj   +1 more source

Rituximab versus tocilizumab in anti-TNF inadequate responder patients with rheumatoid arthritis (R4RA): 16-week outcomes of a stratified, biopsy-driven, multicentre, open-label, phase 4 randomised controlled trial

The Lancet, 2021
Summary Background Although targeted biological treatments have transformed the outlook for patients with rheumatoid arthritis, 40% of patients show poor clinical response, which is mechanistically still unexplained.
F. Humby, P. Durez, M. Buch, M. Lewis, Hasan Rizvi, F. Rivellese, A. Nerviani, G. Giorli, A. Mahto, C. Montecucco, B. Lauwerys, N. Ng, P. Ho, M. Bombardieri, V. Romão, P. Verschueren, S. Kelly, P. P. Sainaghi, N. Gendi, B. Dasgupta, A. Cauli, P. Reynolds, J. Cañete, R. Moots, P. Taylor, C. Edwards, J. Isaacs, P. Sasieni, E. Choy, C. Pitzalis, C. Thompson, S. Bugatti, M. Bellan, M. Congia, C. Holroyd, A. Pratt, J. E. Cabral da Fonseca, L. White, Louise Warren, Joanna Peel, R. Hands, L. Fossati-Jimack, G. Hadfield, G. Thorborn, J. Ramírez, R. Celis   +45 more
semanticscholar   +1 more source

Rituximab or Cyclophosphamide in the Treatment of Membranous Nephropathy: The RI-CYCLO Randomized Trial.

Journal of the American Society of Nephrology, 2021
BACKGROUND A cyclic corticosteroid-cyclophosphamide regimen is the first-line therapy for membranous nephropathy. Compared with this regimen, rituximab therapy might have a more favorable safety profile, but a head-to-head comparison is lacking ...
F. Scolari, Elisa Delbarba, D. Santoro, L. Gesualdo, A. Pani, N. Dallera, Laila-Yasmin Mani, M. Santostefano, S. Feriozzi, M. Quaglia, G. Boscutti, A. Ferrantelli, C. Marcantoni, P. Passerini, R. Magistroni, F. Alberici, G. Ghiggeri, C. Ponticelli, P. Ravani   +18 more
semanticscholar   +1 more source

Rituximab (Rituxan) [PDF]

American Journal of Neuroradiology, 2010
Rituximab is a monoclonal antibody that was first approved by the FDA as an antineoplastic agent designed to treat B-cell malignancies. This article will review the mechanism of action and clinical role of this anti-B-cell agent.
David T, Selewski, G V, Shah, R J, Mody, P A, Rajdev, S K, Mukherji   +4 more
openaire   +2 more sources

Rituximab plus bendamustine or chlorambucil for chronic lymphocytic leukemia: primary analysis of the randomized, open-label MABLE study

Haematologica, 2018
MABLE investigated the efficacy and safety of rituximab plus bendamustine or rituximab plus chlorambucil in fludarabine-ineligible patients with chronic lymphocytic leukemia.
Anne-Sophie Michallet, Melih Aktan, Wolfgang Hiddemann, Osman Ilhan, Peter Johansson, Kamel Laribi, Balkis Meddeb, Carol Moreno, João Raposo, Anna Schuh, Ali Ünal, Tom Widenius, Alf Bernhardt, Kerstin Kellershohn, Dimitri Messeri, Stuart Osborne, Véronique Leblond   +16 more
doaj   +1 more source

COVID-19 outcomes in patients with inflammatory rheumatic and musculoskeletal diseases treated with rituximab: a cohort study

The Lancet Rheumatology, 2021
Background Various observations have suggested that the course of COVID-19 might be less favourable in patients with inflammatory rheumatic and musculoskeletal diseases receiving rituximab compared with those not receiving rituximab.
J. Avouac, É. Drumez, E. Hachulla, R. Seror, S. Georgin-lavialle, S. el Mahou, E. Pertuiset, T. Pham, H. Marotte, A. Servettaz, F. Domont, P. Chazerain, M. Devaux, P. Claudepierre, V. Langlois, A. Mékinian, A. Maria, B. Banneville, B. Fautrel, J. Pouchot, Thierry Thomas, R. Flipo, C. Richez   +22 more
semanticscholar   +1 more source

Course of neuromyelitis optica during inadvertent pregnancy in a patient treated with rituximab [PDF]

, 2009
In neuromyelitis optica (NMO), the monoclonal B-cell antibody rituximab is a therapeutic option. Little is known about the course of NMO and the safety of rituximab during pregnancy.
Hohlfeld, R., Pellkofer, H. L., Suessmair, C., Schulze, A., Kümpfel, Tania   +4 more
core   +1 more source